Clinical Trial

Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 21, 2022 (before its estimated May 19, 2024 completion). Its status may not reflect the trial's current state.
Summary
Complete surgical resection is the standard treatment in early-stage lung cancer. However, the patients with early resected Epidermal Growth Factor Receptor(EGFR)-mutated lung cancers have high recurrence rate. The efficacy of neoadjuvant treatment by first-generation EGFR-Tyrosine Kinase Inhibitor(TKI) has been demonstrated, however, that of the third-generation EGFR-TKI(lazertinib) has not yet been fully investigated. The aim of this study is to evaluate the efficacy of neoadjuvant Lazertinib in resectable EGFR mutation-positive NSCLC and clinical application of extracellular vesicles(EVs) based BALF liquid biopsy to identify EGFR mutation without invasive tissue biopsy.
Trial Details
NCT Number NCT05469022
Lead Sponsor Konkuk University Medical Center
Collaborators: Yuhan Corporation
Conditions Non Small Cell Lung Cancer
Enrollment 40 participants
Start Date 2022-05-19
Primary Completion 2024-05-19 (estimated)
Study Completion 2027-05-19 (estimated)
Updated on ClinicalTrials.gov 2022-07-21